Edition:
United Kingdom

Antares Pharma Inc (ATRS.OQ)

ATRS.OQ on NASDAQ Stock Exchange Capital Market

3.34USD
19 Oct 2018
Change (% chg)

$-0.09 (-2.62%)
Prev Close
$3.43
Open
$3.43
Day's High
$3.49
Day's Low
$3.34
Volume
165,655
Avg. Vol
239,415
52-wk High
$3.93
52-wk Low
$1.59

Chart for

About

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.... (more)
No analyst recommendations are available for .

Overall

Beta: 0.28
Market Cap(Mil.): €518.56
Shares Outstanding(Mil.): 156.41
Dividend: --
Yield (%): --

Financials

  ATRS.OQ Industry Sector
P/E (TTM): -- 32.09 33.64
EPS (TTM): -2.95 -- --
ROI: -- 13.81 14.27
ROE: -- 16.56 15.99

Antares Pharma's testosterone drug gets FDA approval

The U.S. Food and Drug Administration on Monday approved Antares Pharma Inc's injectable drug to treat low testosterone levels in men, the company said, nearly a year after being rejected.

01 Oct 2018

UPDATE 1-Antares Pharma's testosterone drug gets FDA approval

Oct 1 The U.S. Food and Drug Administration on Monday approved Antares Pharma Inc's injectable drug to treat low testosterone levels in men, the company said, nearly a year after being rejected.

01 Oct 2018

Antares Pharma's testosterone drug gets FDA approval

Oct 1 The U.S. Food and Drug Administration on Monday approved Antares Pharma Inc's drug to treat low testosterone levels in men, the company said, nearly a year after rejecting the injection.

01 Oct 2018

MEDIA-Russia to supply U.S. with new rocket engines - Kommersant

* Russian engine maker Energomash has signed a new contract to supply four RD-181 rocket engines to U.S. aerospace firm Orbital ATK by 2021 for its Antares rocket, the Kommersant newspaper wrote on Tuesday.

04 Sep 2018

BRIEF-Antares Pharma Reports Q1 Loss Per Share Of $0.04

* ANTARES PHARMA REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS

08 May 2018

Competitors

Earnings vs. Estimates

No consensus analysis data available.